Jin X, Lian JS, Hu JH, et al. - From the Zhejiang province, 74 confirmed COVID-19 cases with GI symptoms were analyzed in order to determine epidemiological, clinical and virological characteristics. Among the included 651 COVID-19 hospital patients, at least one GI symptom (nausea, vomiting or diarrhoea) was reported in 74 (11.4%; average age of 46.14 years), with 4-day incubation period; 10.8% of 74 patients had preexisting liver disease. Significantly higher severe/critical types and family clustering were observed among patients with COVID-19 with GI symptoms vs those without GI symptoms. Significantly higher rates of fever > 38.5°C, fatigue, shortness of breath and headache were observed in patients with COVID-19 with GI symptoms. Treatment comprised low-dose glucocorticoids and antibiotics in 14.86% and 41.89% of patients, respectively. Risk factors for severe/critical type were sputum production and increased lactate dehydrogenase/glucose levels. Sequence mutation of SARS-CoV-2 with m⁶A methylation and changed binding capacity with ACE2 were observed in bioinformatics.In view of these novel features of COVID-19 cases with GI symptoms outside Wuhan, they recommend paying increased attention to patients with COVID-19 with non-classic symptoms to protect health providers.